




## Supplemental figures



**Supplement Fig.S1** BI suppresses LPS-mediated increase in T cell chemokine IL-16 but not CCL20 levels, in the BAL (A-C). LPS increases the levels of all three T cell chemokines CCL20 (MIP-3α, A), IL-16 (B) and IP-10 (C). Although BI does not affect the LPS-mediated increase in the levels of CCL20, it decreases the levels of IL-16 and IP-10. BI also shows a small, but not significant, decrease in IL-16 levels in the serum. N=5 for each condition; +, mean; \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ;  $p = 0.0858$  for LPS vs. BI+LPS for IP-10 in BAL.



**Supplemental Fig. S2.** BI does not affect LPS-mediated Th2 cytokine response, but induces Th17-suppressing cytokine IL-2. BI does not alter LPS-mediated increase in Th2 cytokines such as IL-5, IL-4, IL-13 and IL-31, Th2 cell survival promoting cytokines IL-9 and IL-15, but promotes Th17-suppressing cytokine IL-2 (A-H). LPS increases the levels of IL-4, IL-13 and IL-31, but not IL-5. BI does not affect the levels of these cytokines (A-D). No treatment conditions induce IL-5 promoting cytokine IL-33. LPS induces Th2 cell survival cytokines IL-9 and IL-15, and BI does not affect the levels of these cytokines (E-H). Only BI+LPS condition increases IL-2. Neither LPS nor BI significantly increases any of these cytokines in the serum. N=5 for each condition; +, mean; \*,  $p < 0.05$ ; \*\*\*,  $p < 0.001$ ;  $p = 0.9240$ , BI vs. BI+LPS for IL-15 in BAL.



**Supplemental Fig. S3.** BI differentially affects some of the Th17-regulatory cytokines during LPS-mediated lung inflammation. LPS increases IL-23 levels and BI does not reduce the levels of this Th17 stimulating cytokine (A). LPS or BI does not significantly affect the levels of IL27p28/IL-30, and IL-10 (B and C). BI does not suppress LPS-mediated increase in inflammatory cytokines IL17F (D), IL-17A/F heterodimer (E) and IL-22 (F) levels. LPS, but not LPS+BI induces IL-21 levels (G). LPS or BI does not significantly affect the levels of Th17-related cytokines in serum. N=5 for each condition; +, mean; \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ;  $p = 9085$ , Sham vs. BI and  $p = 0.6967$ , LPS vs. BI+LPS for IL-27 p28/IL-30,  $p = 0.1372$ , LPS vs. BI+LPS for IL-22 and  $p = 0.2776$ , LPS vs. BI+LPS for IL-21 in panels B, F and G, respectively, for BAL samples.